NO863029L - Farmasoeytisk doseringsenhet. - Google Patents
Farmasoeytisk doseringsenhet.Info
- Publication number
- NO863029L NO863029L NO863029A NO863029A NO863029L NO 863029 L NO863029 L NO 863029L NO 863029 A NO863029 A NO 863029A NO 863029 A NO863029 A NO 863029A NO 863029 L NO863029 L NO 863029L
- Authority
- NO
- Norway
- Prior art keywords
- tpa
- acid
- dosage unit
- solution
- freeze
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75978585A | 1985-07-29 | 1985-07-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO863029D0 NO863029D0 (no) | 1986-07-28 |
| NO863029L true NO863029L (no) | 1987-01-30 |
Family
ID=25056946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO863029A NO863029L (no) | 1985-07-29 | 1986-07-28 | Farmasoeytisk doseringsenhet. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0211592A3 (pt) |
| JP (1) | JPS6236332A (pt) |
| KR (1) | KR870000918A (pt) |
| CN (1) | CN86105526A (pt) |
| AU (1) | AU593566B2 (pt) |
| DK (1) | DK352686A (pt) |
| ES (1) | ES2000743A6 (pt) |
| FI (1) | FI863077A7 (pt) |
| GR (1) | GR861961B (pt) |
| HU (1) | HU198264B (pt) |
| NO (1) | NO863029L (pt) |
| PH (1) | PH22989A (pt) |
| PT (1) | PT83075B (pt) |
| ZA (1) | ZA865652B (pt) |
| ZW (1) | ZW14486A1 (pt) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE462893B (sv) * | 1985-05-28 | 1990-09-17 | Wellcome Found | Vattenhaltig parenteral loesning av vaevnadsplasminogenaktivator och saett foer framstaellning av den |
| US4929444A (en) * | 1985-05-28 | 1990-05-29 | Burroughs Wellcome Co. | Low pH pharmaceutical formulation containing t-PA |
| US4777043A (en) * | 1985-12-17 | 1988-10-11 | Genentech, Inc. | Stabilized human tissue plasminogen activator compositions |
| US5034225A (en) * | 1985-12-17 | 1991-07-23 | Genentech Inc. | Stabilized human tissue plasminogen activator compositions |
| DE3822557C2 (de) * | 1987-07-10 | 1998-07-02 | Ciba Geigy Ag | Arzneimittel, enthaltend Somatostatine |
| US4929560A (en) * | 1988-02-03 | 1990-05-29 | Damon Biotech, Inc. | Recovery of tissue plasminogen activator |
| DE3806562A1 (de) * | 1988-03-01 | 1989-09-14 | Alpha Therapeutic Gmbh | Zweikammerspritze mit einer fuellung aus aktivitaetsempfindlichem humanen protein als wirkstoff |
| US5270198A (en) * | 1988-05-20 | 1993-12-14 | Genentech, Inc. | DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells |
| US5342616A (en) * | 1988-06-20 | 1994-08-30 | The Wellcome Foundation Limited | Method of administering tissue plasminogen activator |
| GB8814604D0 (en) * | 1988-06-20 | 1988-07-27 | Wellcome Found | Medicaments |
| US5262170A (en) * | 1988-09-02 | 1993-11-16 | Genentech, Inc. | Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells |
| US5714145A (en) * | 1988-09-02 | 1998-02-03 | Genentech, Inc. | Tissue plasminogen activator having zymogenic or fibrin specific properties |
| DE3835350A1 (de) * | 1988-10-17 | 1990-04-19 | Boehringer Mannheim Gmbh | Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern |
| US4980165A (en) * | 1989-01-27 | 1990-12-25 | Genetics Institute, Inc. | Pharmaceutical formulations of plasminogen activator proteins |
| CA2027936C (en) | 1989-10-23 | 2001-07-24 | Smithkline Beecham Corporation | Cyclic anti-aggregatory peptides |
| US5366730A (en) * | 1989-12-20 | 1994-11-22 | Boehringer Mannheim Gmbh | Stabilized compositions having human tissue type plasminogen activator enzymatic activity |
| DE3942143A1 (de) * | 1989-12-20 | 1991-06-27 | Boehringer Mannheim Gmbh | T-pa pro stabilisierung |
| DE3942145A1 (de) * | 1989-12-20 | 1991-06-27 | Boehringer Mannheim Gmbh | T-pa-solubilisierung |
| DE3942142A1 (de) * | 1989-12-20 | 1991-06-27 | Boehringer Mannheim Gmbh | Stabilisierung von glykosyliertem t-pa |
| DE3942144A1 (de) * | 1989-12-20 | 1991-06-27 | Boehringer Mannheim Gmbh | Stabilisierung von k1k2p pro |
| DE3942141A1 (de) * | 1989-12-20 | 1991-06-27 | Boehringer Mannheim Gmbh | K2p pro-stabilisierung |
| JPH06506459A (ja) * | 1991-04-16 | 1994-07-21 | ロシュ ダイアグノスティックス ゲーエムベーハー | プラスミノーゲン活性化剤を含有する多重ボーラス投与用医薬パッケージユニット |
| US5272076A (en) * | 1991-06-13 | 1993-12-21 | Eli Lilly And Company | Compounds and methods for treatment of thromboembolic disorders using an adduct of t-PA |
| US5747447A (en) * | 1992-04-30 | 1998-05-05 | Cor Therapeutics | Stable polypeptide composition |
| ATE155816T1 (de) * | 1992-06-03 | 1997-08-15 | Genentech Inc | Varianten des gewebeplasminogenaktivators mit verbesserter therapeutischer wirkung |
| EP2266599B1 (en) | 2004-07-26 | 2014-04-16 | Merz Pharma GmbH & Co. KGaA | Therapeutic composition with a botulinum neurotoxin |
| KR102194891B1 (ko) | 2020-07-08 | 2020-12-28 | 대상 주식회사 | 계란프라이 조리장치 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8003402A (nl) * | 1980-06-11 | 1982-01-04 | Leuven Res & Dev Vzw | Nieuwe plasminogeen-activator en farmaceutisch preparaat met trombolytische werking. |
| JPS59196824A (ja) * | 1983-04-21 | 1984-11-08 | Kowa Co | 吸着防止剤 |
| SE462893B (sv) * | 1985-05-28 | 1990-09-17 | Wellcome Found | Vattenhaltig parenteral loesning av vaevnadsplasminogenaktivator och saett foer framstaellning av den |
| US4929444A (en) * | 1985-05-28 | 1990-05-29 | Burroughs Wellcome Co. | Low pH pharmaceutical formulation containing t-PA |
| JPH0672105B2 (ja) * | 1985-10-02 | 1994-09-14 | 持田製薬株式会社 | 血栓溶解剤及びその製法 |
-
1986
- 1986-07-23 ZW ZW144/86A patent/ZW14486A1/xx unknown
- 1986-07-24 DK DK352686A patent/DK352686A/da not_active Application Discontinuation
- 1986-07-24 ES ES8600558A patent/ES2000743A6/es not_active Expired
- 1986-07-25 GR GR861961A patent/GR861961B/el unknown
- 1986-07-28 KR KR1019860006133A patent/KR870000918A/ko not_active Withdrawn
- 1986-07-28 NO NO863029A patent/NO863029L/no unknown
- 1986-07-28 PH PH34074A patent/PH22989A/en unknown
- 1986-07-28 PT PT83075A patent/PT83075B/pt unknown
- 1986-07-28 HU HU863218A patent/HU198264B/hu not_active IP Right Cessation
- 1986-07-28 EP EP86305794A patent/EP0211592A3/en not_active Withdrawn
- 1986-07-28 FI FI863077A patent/FI863077A7/fi not_active Application Discontinuation
- 1986-07-28 CN CN198686105526A patent/CN86105526A/zh active Pending
- 1986-07-29 AU AU60647/86A patent/AU593566B2/en not_active Ceased
- 1986-07-29 ZA ZA865652A patent/ZA865652B/xx unknown
- 1986-07-29 JP JP61179812A patent/JPS6236332A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6236332A (ja) | 1987-02-17 |
| ZA865652B (en) | 1987-11-25 |
| EP0211592A2 (en) | 1987-02-25 |
| AU593566B2 (en) | 1990-02-15 |
| AU6064786A (en) | 1987-02-05 |
| PH22989A (en) | 1989-02-24 |
| HUT42953A (en) | 1987-09-28 |
| ZW14486A1 (en) | 1986-10-22 |
| FI863077L (fi) | 1987-01-30 |
| GR861961B (en) | 1986-11-26 |
| CN86105526A (zh) | 1987-02-04 |
| DK352686D0 (da) | 1986-07-24 |
| ES2000743A6 (es) | 1988-03-16 |
| DK352686A (da) | 1987-01-30 |
| KR870000918A (ko) | 1987-03-10 |
| NO863029D0 (no) | 1986-07-28 |
| FI863077A7 (fi) | 1987-01-30 |
| PT83075B (en) | 1988-07-13 |
| HU198264B (en) | 1989-09-28 |
| FI863077A0 (fi) | 1986-07-28 |
| PT83075A (en) | 1986-08-01 |
| EP0211592A3 (en) | 1988-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO863029L (no) | Farmasoeytisk doseringsenhet. | |
| US5770700A (en) | Liquid factor IX formulations | |
| US5112609A (en) | Acidic formulations of t-PA | |
| EP1232251B1 (en) | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin | |
| US4478829A (en) | Pharmaceutical preparation containing purified fibronectin | |
| CA1340270C (en) | Thrombolytic composition and a process for production thereof | |
| US4968617A (en) | Solid hydrochloride salt of t-PA | |
| US20030026798A1 (en) | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin | |
| EP0410207B1 (en) | Stabilization of highly purified proteins | |
| Smith et al. | Acyl-enzymes as thrombolytic agents in a rabbit model of venous thrombosis | |
| AU623347B2 (en) | Thrombolytic agent | |
| US4837022A (en) | Composition containing tissue plasminogen activator | |
| US20030175264A1 (en) | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin | |
| HU216793B (hu) | Eljárás nem glikozilezett K2P pro t-PA-származékot tartalmazó gyógyszerkészítmény előállítására | |
| US5366730A (en) | Stabilized compositions having human tissue type plasminogen activator enzymatic activity | |
| US6759042B2 (en) | Use of cross-linked, covalently bound urokinase plasminogen activator (scuPA)-urokinase plasminogen activator receptor (suPAR) complex as a fibrinolytic agent | |
| EP0419252A1 (en) | Thrombolytic composition containing tissue type plasminogen activator or derivative thereof | |
| CA2046598C (en) | T-pa solubilisation | |
| JPS62234030A (ja) | ｔＰＡ医薬組成物 | |
| JPS6338327B2 (pt) | ||
| KR960002738B1 (ko) | 유로키나아제를 함유하는 혈정용해제 | |
| JPS6259221A (ja) | 組織プラスミノ−ゲン活性化因子含有組成物 | |
| JPS62120321A (ja) | ｔＰＡ含有医薬組成物 | |
| JPS62123130A (ja) | 水溶性を増加したｔＰＡ含有医薬組成物 | |
| EP0352897A1 (en) | TPA-containing medicaments |